Shadaker Shaun, Sood Ajit, Averhoff Francisco, Suryaprasad Anil, Kanchi Subodh, Midha Vandana, Kamili Saleem, Nasrullah Muazzam, Trickey Adam, Garg Ravinder, Mittal Pramod, Sharma Suresh K, Vickerman Peter, Armstrong Paige A
Division of Viral Hepatitis, Centers for Disease Control and Prevention, NCHHSTP, Atlanta, GA, 30333, USA.
Dayanand Medical College, Department of Gastroenterology, Civil Lines, Tagore Nagar, Ludhiana, Punjab, 141001, India.
J Clin Exp Hepatol. 2022 Sep-Oct;12(5):1310-1319. doi: 10.1016/j.jceh.2022.04.014. Epub 2022 Apr 18.
The prevalence of hepatitis B virus (HBV) infection in Punjab, India, is unknown. Understanding the statewide prevalence and epidemiology can help guide public health campaigns to reduce the burden of disease and promote elimination efforts.
A cross-sectional, population-based survey was conducted from October 2013 to April 2014 using a multistage stratified cluster sampling design. All members of selected households aged ≥5 years were eligible. Participants were surveyed for demographics and risk behaviors; serum samples were tested for total antibody to hepatitis B core (total anti-HBc), hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody (anti-HCV), and HCV RNA. HBsAg-positive specimens were tested for HBV genotype.
A total of 5543 individuals participated in the survey and provided serum samples. The prevalence of total anti-HBc was 15.2% (95% confidence interval [95% CI]: 14.1-16.5) and HBsAg was 1.4% (95% CI: 1.0-1.9). Total anti-HBc positivity was associated with male sex (adjusted odds ratio [aOR] 1.46; 95% CI: 1.21-1.75), older age (aOR 3.31; 95% CI: 2.28-4.79 for ≥60 vs. 19-29 years), and living in a rural area (aOR 2.02; 95% CI: 1.62-2.51). Receipt of therapeutic injections in the past 6 months also increased risk (4-8 injections vs. none; aOR 1.39; 95% CI: 1.05-1.84). Among those positive for total anti-HBc, 10.4% (95% CI: 8.1-13.2) were also anti-HCV positive.
Punjab has a substantial burden of HBV infection. Hepatitis B vaccination programs and interventions to minimize the use of therapeutic injections, particularly in rural areas, should be considered.
印度旁遮普邦的乙型肝炎病毒(HBV)感染率尚不清楚。了解该邦的感染率及流行病学情况有助于指导公共卫生运动,以减轻疾病负担并推动消除乙肝的努力。
2013年10月至2014年4月,采用多阶段分层整群抽样设计进行了一项基于人群的横断面调查。选定家庭中所有年龄≥5岁的成员均符合条件。对参与者进行人口统计学和风险行为调查;检测血清样本中的乙肝核心抗体(抗-HBc)、乙肝表面抗原(HBsAg)、丙型肝炎病毒(HCV)抗体(抗-HCV)和HCV RNA。对HBsAg阳性样本进行HBV基因型检测。
共有5543人参与调查并提供了血清样本。抗-HBc的总体流行率为15.2%(95%置信区间[95%CI]:14.1-16.5),HBsAg为1.4%(95%CI:1.0-1.9)。抗-HBc阳性与男性(调整优势比[aOR]1.46;95%CI:1.21-1.75)、年龄较大(≥60岁与19-29岁相比,aOR 3.31;95%CI:2.28-4.79)以及居住在农村地区(aOR 2.02;95%CI:1.62-2.51)有关。过去6个月接受过治疗性注射也会增加感染风险(4-8次注射与未注射相比;aOR 1.39;95%CI:1.05-1.84)。在抗-HBc阳性者中,10.4%(95%CI:8.1-13.2)同时抗-HCV阳性。
旁遮普邦的HBV感染负担较重。应考虑实施乙肝疫苗接种计划以及采取干预措施,尽量减少治疗性注射的使用,尤其是在农村地区。